Regeneron Pharmaceuticals, Inc.
Corporate Headquarters
777 Old Saw Mill River Road
Tarrytown
New York
10591
United States
Tel: 914-847-7000
Website: https://www.regeneron.com/
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Stock Symbol: REGN
Stock Exchange: NASDAQ
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Learn more about how our team produces the highest-quality treatments for patients at https://www.regeneron.com/.
1400 articles about Regeneron Pharmaceuticals, Inc.
-
Will Regeneron's New Drug Praluent Break The Bank?
8/5/2015
-
Regeneron Reports Second Quarter 2015 Financial And Operating Results
8/4/2015
-
Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief
7/29/2015
-
Sanofi and Regeneron Ink $2.2 Billion Immuno-Oncology, PD-1 Inhibitor Deal
7/28/2015
-
Sanofi, Regeneron’s $15,000-a-Year Heart Drug May Trigger New Cost Concerns
7/27/2015
-
Regeneron, Sanofi's Big New Cholesterol Drug Praluent Wins European Green Light
7/24/2015
-
FDA Approves Cholesterol Drug Praluent From Regeneron, Sanofi
7/24/2015
-
Amgen Beats Sanofi/Regeneron to European Market for Cholesterol Drug, but Race is Still on for U.S. Market
7/23/2015
-
Regeneron, Sanofi's Praluent Delivers in Late Stage Trial
7/9/2015
-
Regeneron And Sanofi Announce Phase III Results Showing LDL-C Reductions Of More Than 60 Percent In Japanese Patients Treated With Praluent(Alirocumab) Injection
7/9/2015
-
Regeneron To Report Second Quarter 2015 Financial And Operating Results And Host Conference Call And Webcast On August 4, 2015
7/8/2015
-
Regeneron Rapid Response Platform For Emerging Infectious Diseases Described In Proceedings Of The National Academy of Sciences Publication
6/30/2015
-
Regeneron Release: EYLEA (aflibercept) Injection Receives Approval In Japan For The Treatment Of Retinal Vein Occlusion
6/26/2015
-
Regeneron Announces 2015 Winners Of The Regeneron Prize For Creative Innovation
6/25/2015
-
Analysts Question Avalanche Biotech Clinical Data, Could Jeopardize Regeneron Deal
6/18/2015
-
Why Is Amgen Rising And Regeneron Falling?
6/12/2015
-
FDA Advisors Back Regeneron, Sanofi's New Heart Drug With Limits
6/11/2015
-
Regeneron Trading Halted While FDA Considers New Drug Developed With Sanofi
6/10/2015
-
FDA Advisory Committee Recommends Approval Of Regeneron And Regeneron's Praluent (Alirocumab) Injection For Patients With Hypercholesterolemia
6/10/2015
-
FDA Staff Says Regeneron, Sanofi Drug Cuts Cholesterol But Questions Benefits
6/9/2015